Several specific populations may require a lower starting dose of Eriacta 100 Mg (sildenafil citrate) due to various factors such as age, underlying health conditions, and medication interactions. These populations include:

Elderly Individuals: Older adults may metabolize medications more slowly and may be more sensitive to the effects of sildenafil citrate. Therefore, they may require a lower starting dose to minimize the risk of side effects such as headache, dizziness, or flushing.

Patients with Liver Impairment: Individuals with liver impairment may have reduced clearance of sildenafil citrate from the body, leading to higher drug levels and an increased risk of adverse effects. A lower starting dose may be necessary in patients with moderate to severe liver impairment.

Patients with Kidney Impairment: Patients with kidney impairment may experience reduced clearance of sildenafil citrate, potentially leading to higher drug levels and an increased risk of side effects. A lower starting dose may be appropriate in patients with moderate to severe kidney impairment.

Patients Taking Concomitant Medications: Certain medications can interact with sildenafil citrate and potentiate its effects or increase the risk of adverse reactions. Patients taking medications such as alpha-blockers, nitrates, antihypertensives, or protease inhibitors may require a lower starting dose of sildenafil citrate to minimize the risk of interactions.

Patients with Cardiovascular Conditions: Patients with cardiovascular conditions such as coronary artery disease, hypertension, or a history of stroke may be at increased risk of cardiovascular events associated with the use of sildenafil citrate. A lower starting dose may be advisable in these patients, especially if they have unstable cardiovascular conditions.

Patients with Anatomical Deformities of the Penis: Patients with anatomical deformities of the penis, such as Peyronie's disease, may be more susceptible to adverse effects from sildenafil citrate. A lower starting dose may be recommended in these patients to minimize the risk of complications.

Patients with Retinal Disorders: Patients Eriacta 100 Mg retinal disorders such as retinitis pigmentosa may be at increased risk of visual disturbances associated with the use of sildenafil citrate. A lower starting dose may be appropriate in these patients, and close monitoring of visual function is recommended.

Before initiating treatment with Eriacta 100 Mg or any medication containing sildenafil citrate, healthcare providers should carefully assess individual patient factors and consider the potential need for a lower starting dose in certain populations to optimize safety and efficacy. It's essential for patients to discuss their medical history and any concerns with their healthcare provider to ensure that the treatment plan is tailored to their specific needs.